Macsen Labs Group Plans for the Construction of New Manufacturing Facility in India
Introduction:
Macsen Labs Group has announced the commencement of construction of a new Active Pharmaceutical Ingredient (API) manufacturing facility in India.
Features:
The new facility spans 25,000 square meters, five times larger than the current infrastructure at Macsen Drugs, a USFDA-inspected, TGA-GMP, and WHO-GMP certified manufacturing unit.
The facility will include multiple API production blocks designed to support scalability and advanced manufacturing processes for diverse therapeutic applications.
The initial phase, with an investment of approximately INR 75 crore, includes two multistorey API production blocks with a combined reactor capacity of 100 KL (stainless steel and glass-lined reactors).
A new dedicated, state-of-the-art R&D center covers an area of 15,000 square feet.
Production activities at the new facility are expected to begin by the end of 2025.
Specifications:
Name : Macsen Labs Group
Type : New Construction
Year : 2025
